187 related articles for article (PubMed ID: 20056761)
1. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
Robinson ES; Matulonis UA; Ivy P; Berlin ST; Tyburski K; Penson RT; Humphreys BD
Clin J Am Soc Nephrol; 2010 Mar; 5(3):477-83. PubMed ID: 20056761
[TBL] [Abstract][Full Text] [Related]
2. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Matulonis UA; Berlin S; Ivy P; Tyburski K; Krasner C; Zarwan C; Berkenblit A; Campos S; Horowitz N; Cannistra SA; Lee H; Lee J; Roche M; Hill M; Whalen C; Sullivan L; Tran C; Humphreys BD; Penson RT
J Clin Oncol; 2009 Nov; 27(33):5601-6. PubMed ID: 19826113
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
[TBL] [Abstract][Full Text] [Related]
4. Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.
Al-Huniti N; Petersson K; Tang W; Masson E; Li J
Br J Clin Pharmacol; 2018 Apr; 84(4):726-737. PubMed ID: 29274100
[TBL] [Abstract][Full Text] [Related]
5. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Lee JM; Cimino-Mathews A; Peer CJ; Zimmer A; Lipkowitz S; Annunziata CM; Cao L; Harrell MI; Swisher EM; Houston N; Botesteanu DA; Taube JM; Thompson E; Ogurtsova A; Xu H; Nguyen J; Ho TW; Figg WD; Kohn EC
J Clin Oncol; 2017 Jul; 35(19):2193-2202. PubMed ID: 28471727
[TBL] [Abstract][Full Text] [Related]
6. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Goodwin R; Ding K; Seymour L; LeMaître A; Arnold A; Shepherd FA; Dediu M; Ciuleanu T; Fenton D; Zukin M; Walde D; Laberge F; Vincent M; Ellis PM; Laurie SA;
Ann Oncol; 2010 Nov; 21(11):2220-2226. PubMed ID: 20427348
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Hong DS; Garrido-Laguna I; Ekmekcioglu S; Falchook GS; Naing A; Wheler JJ; Fu S; Moulder SL; Piha-Paul S; Tsimberidou AM; Wen Y; Culotta KS; Anderes K; Davis DW; Liu W; George GC; Camacho LH; Percy Ivy S; Kurzrock R
Cancer; 2014 Jul; 120(14):2164-73. PubMed ID: 24752867
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Hirte H; Lheureux S; Fleming GF; Sugimoto A; Morgan R; Biagi J; Wang L; McGill S; Ivy SP; Oza AM
Gynecol Oncol; 2015 Jul; 138(1):55-61. PubMed ID: 25895616
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Ramalingam SS; Belani CP; Mack PC; Vokes EE; Longmate J; Govindan R; Koczywas M; Ivy SP; Gandara DR
J Thorac Oncol; 2010 Aug; 5(8):1279-84. PubMed ID: 20559150
[TBL] [Abstract][Full Text] [Related]
10. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
Campbell NP; Kunnavakkam R; Leighl N; Vincent MD; Gandara DR; Koczywas M; Gitlitz BJ; Agamah E; Thomas SP; Stadler WM; Vokes EE; Kindler HL
Lung Cancer; 2012 Oct; 78(1):76-80. PubMed ID: 22831987
[TBL] [Abstract][Full Text] [Related]
11. Model-based treatment optimization of a novel VEGFR inhibitor.
Keizer RJ; Gupta A; Shumaker R; Beijnen JH; Schellens JH; Huitema AD
Br J Clin Pharmacol; 2012 Aug; 74(2):315-26. PubMed ID: 22295876
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion.
Mulder SF; Boers-Sonderen MJ; van der Heijden HF; Vissers KC; Punt CJ; van Herpen CM
Target Oncol; 2014 Dec; 9(4):331-8. PubMed ID: 24446026
[TBL] [Abstract][Full Text] [Related]
13. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
Yamamoto N; Tamura T; Yamamoto N; Yamada K; Yamada Y; Nokihara H; Fujiwara Y; Takahashi T; Murakami H; Boku N; Yamazaki K; Puchalski TA; Shin E
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1165-72. PubMed ID: 19308410
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.
Curwen JO; Musgrove HL; Kendrew J; Richmond GH; Ogilvie DJ; Wedge SR
Clin Cancer Res; 2008 May; 14(10):3124-31. PubMed ID: 18483380
[TBL] [Abstract][Full Text] [Related]
15. Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.
Becker MA; Farzan T; Harrington SC; Krempski JW; Weroha SJ; Hou X; Kalli KR; Wong TW; Haluska P
Mol Cancer Ther; 2013 Dec; 12(12):2909-16. PubMed ID: 24130056
[TBL] [Abstract][Full Text] [Related]
16. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
17. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
Langenberg MH; van Herpen CM; De Bono J; Schellens JH; Unger C; Hoekman K; Blum HE; Fiedler W; Drevs J; Le Maulf F; Fielding A; Robertson J; Voest EE
J Clin Oncol; 2009 Dec; 27(36):6152-9. PubMed ID: 19901116
[TBL] [Abstract][Full Text] [Related]
18. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
19. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
Li J; Al-Huniti N; Henningsson A; Tang W; Masson E
Br J Clin Pharmacol; 2017 Aug; 83(8):1723-1733. PubMed ID: 28213941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
